Navarro Ana M, Delgado Julio, Muñoz-Cano Rosa M, Dordal M Teresa, Valero Antonio, Quirce Santiago
UGC of Allergy, Hospital El Tomillar , Carretera Alcalá - Dos Hermanas km 6, 41700 Dos Hermanas, Seville Spain.
UGC of Allergy, Hospital Universitario Virgen Macarena, Seville, Spain.
Clin Transl Allergy. 2017 May 18;7:16. doi: 10.1186/s13601-017-0150-2. eCollection 2017.
The variability of symptoms observed in patients with respiratory allergy often hampers classification based on the criteria proposed in guidelines on rhinitis and asthma.
We assessed specific aspects of allergic respiratory disease (ARD) that are not explicitly addressed in the guidelines in order to issue specific recommendations and thus optimize clinical practice.
Using the Delphi technique, 40 Spanish allergists were surveyed to reach consensus on 71 items related to ARD.
Consensus was achieved for 95.7% of the items. These included the following: the clinical manifestations of ARD are heterogeneous and individual airborne allergens can be related to specific clinical profiles; the optimal approach in patients with ARD is based on the global assessment of rhinoconjunctivitis and asthma; aeroallergens are largely responsible for the clinical features and severity of the disease; and clinical expression is associated with the period of environmental exposure to the allergen. Pharmacological treatment of ARD is often based on the intensity of symptoms recorded during previous allergen exposures and cannot always be administered following a step-up approach, as recommended in clinical practice guidelines. Allergen immunotherapy (AIT) is the only option for overall treatment of respiratory symptoms using an etiological approach. AIT can modify the prognosis of ARD and should therefore be considered a valuable first-line treatment.
The present study highlights gaps in current asthma and rhinitis guidelines and addresses specific aspects of ARD, such as global assessment of both asthma and rhinitis or the specific role of variable allergen exposure in the clinical expression of the disease.
呼吸道过敏患者中观察到的症状变异性常常妨碍根据鼻炎和哮喘指南中提出的标准进行分类。
我们评估了指南中未明确涉及的过敏性呼吸道疾病(ARD)的具体方面,以便发布具体建议,从而优化临床实践。
采用德尔菲技术,对40名西班牙过敏症专科医生进行调查,以就与ARD相关的71个项目达成共识。
95.7%的项目达成了共识。这些包括:ARD的临床表现具有异质性,个体空气传播过敏原可能与特定临床特征相关;ARD患者的最佳治疗方法基于对鼻结膜炎和哮喘的整体评估;空气过敏原在很大程度上决定了疾病的临床特征和严重程度;临床表型与环境暴露于过敏原的时期有关。ARD的药物治疗通常基于先前过敏原暴露期间记录的症状强度,并不总是能按照临床实践指南中建议的逐步治疗方法进行给药。过敏原免疫疗法(AIT)是使用病因学方法全面治疗呼吸道症状的唯一选择。AIT可以改变ARD的预后,因此应被视为一种有价值的一线治疗方法。
本研究突出了当前哮喘和鼻炎指南中的差距,并阐述了ARD的具体方面,如哮喘和鼻炎的整体评估或可变过敏原暴露在疾病临床表型中的特定作用。